Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

The tumor suppressor activity of SOCS-1.

Rottapel R, Ilangumaran S, Neale C, La Rose J, Ho JM, Nguyen MH, Barber D, Dubreuil P, de Sepulveda P.

Oncogene. 2002 Jun 27;21(28):4351-62.

2.

The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.

Iwamoto T, Senga T, Naito Y, Matsuda S, Miyake Y, Yoshimura A, Hamaguchi M.

Oncogene. 2000 Sep 28;19(41):4795-801.

4.

v-Abl signaling disrupts SOCS-1 function in transformed pre-B cells.

Limnander A, Danial NN, Rothman PB.

Mol Cell. 2004 Aug 13;15(3):329-41.

5.
6.

The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2.

Kamizono S, Hanada T, Yasukawa H, Minoguchi S, Kato R, Minoguchi M, Hattori K, Hatakeyama S, Yada M, Morita S, Kitamura T, Kato H, Nakayama Ki, Yoshimura A.

J Biol Chem. 2001 Apr 20;276(16):12530-8. Epub 2001 Jan 19.

7.

Suppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signaling.

Bayle J, Letard S, Frank R, Dubreuil P, De Sepulveda P.

J Biol Chem. 2004 Mar 26;279(13):12249-59. Epub 2004 Jan 5.

8.

Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function.

Flowers LO, Johnson HM, Mujtaba MG, Ellis MR, Haider SM, Subramaniam PS.

J Immunol. 2004 Jun 15;172(12):7510-8.

9.

The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells.

Monni R, Santos SC, Mauchauffe M, Berger R, Ghysdael J, Gouilleux F, Gisselbrecht S, Bernard O, Penard-Lacronique V.

Oncogene. 2001 Feb 15;20(7):849-58.

10.

Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells.

Lacronique V, Boureux A, Monni R, Dumon S, Mauchauffé M, Mayeux P, Gouilleux F, Berger R, Gisselbrecht S, Ghysdael J, Bernard OA.

Blood. 2000 Mar 15;95(6):2076-83.

11.

Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.

Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE, Arlinghaus RB.

Oncogene. 2001 Sep 27;20(43):6188-95.

12.

Stat1 associates with c-kit and is activated in response to stem cell factor.

Deberry C, Mou S, Linnekin D.

Biochem J. 1997 Oct 1;327 ( Pt 1):73-80.

13.

ARG tyrosine kinase activity is inhibited by STI571.

Okuda K, Weisberg E, Gilliland DG, Griffin JD.

Blood. 2001 Apr 15;97(8):2440-8.

14.

Insulin induces suppressor of cytokine signaling-3 tyrosine phosphorylation through janus-activated kinase.

Peraldi P, Filloux C, Emanuelli B, Hilton DJ, Van Obberghen E.

J Biol Chem. 2001 Jul 6;276(27):24614-20. Epub 2001 Apr 26.

15.

Role of tyrosine 441 of interferon-gamma receptor subunit 1 in SOCS-1-mediated attenuation of STAT1 activation.

Qing Y, Costa-Pereira AP, Watling D, Stark GR.

J Biol Chem. 2005 Jan 21;280(3):1849-53. Epub 2004 Nov 1.

16.

Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling.

Pezet A, Favre H, Kelly PA, Edery M.

J Biol Chem. 1999 Aug 27;274(35):24497-502.

17.

Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.

Ling X, Ma G, Sun T, Liu J, Arlinghaus RB.

Cancer Res. 2003 Jan 15;63(2):298-303.

18.
19.
20.

SOCS-1, -2, -3: selective targets and functions downstream of the prolactin receptor.

Tomic S, Chughtai N, Ali S.

Mol Cell Endocrinol. 1999 Dec 20;158(1-2):45-54.

PMID:
10630404
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk